The Psychopharmacology article, “Long-Acting Injectable Antipsychotic Medications: Why Aren’t They Used as Often as Oral Formulations,” by Barbara J. Limandri, PhD, PMHNP, BC, which was published in the March 2019 issue of the Journal of Psychosocial Nursing and Mental Health Services (volume 57, issue 3, pp. 7-10), has been amended to include factual corrections. Errors were identified subsequent to its original publication. On page 8, the following statements have been changed: The first injection of paliperidone palmitate (Invega Sustenna®) is 234 mg on treatment day 1 followed by an injection of 156 mg 1 week later. Thereafter, the recommended maintenance dosage is 117 mg on a monthly basis. On page 9, Table 1 has been changed to include 9 mg = 156 mg for Oral to LAI Dose Conversion/Administration Interval for Paliperidone palmitate (Invega Sustenna®), as well as footnotes regarding paliperidone palmitate and haloperidol decanoate conversions. The online article and its erratum are considered the version of record.

doi:10.3928/02793695-20190920-01